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Objective To assess the short-term and 1-year outcomes of children with fibromyalgia treated with intensive
physical and occupational therapy (PT/OT) and psychotherapy.
Study designChildrenwith fibromyalgia seenat a tertiary care hospitalwere treatedwith 5-6hours of intensivePT/
OT daily and at least 4 hours of psychosocial services weekly. All medications used for fibromyalgia were discontin-
ued. Children underwent standardized testing, including a visual analog scale for pain; the Bruininks-Oseretsky Test
of Motor Performance, Second Edition; the Bruce treadmill protocol; the Functional Disability Inventory; the Pain
Stages of Change Questionnaire, adolescent version; and the Pediatric Quality of Life Inventory, Teen Report, at
3 time points: at program entry, at the end of the intensive program, and 1 year after the end of the program.
Results Sixty-four children (median age, 16 years; 95% Caucasian; 94% female; median duration of symptoms,
21 months) were studied. The mean pain score decreased significantly from program entry to the end of the pro-
gram (from 66 of 100 to 25 of 100; P = .001). At the 1-year follow-up, 33% reported no pain. All measures of function
on the Bruininks-Oseretsky Test of Motor Performance, Second Edition improved significantly and remained at that
level or continued to improve over the subsequent year. Themean Bruce treadmill protocol time first increased from
588 seconds to 801 seconds (P < .001) and then dropped to 750 seconds (P = .005), which is at the 90th percentile
for age and sex. All Pain Stages of Change Questionnaire, adolescent version subset scores improved significantly
initially and were stable or improved at 1 year, as did the Pediatric Quality of Life Inventory, Teen Report total score.
Conclusion Children with fibromyalgia can be successfully treated without medications with a very intensive PT/
OT and psychotherapy program. They have significantly improved pain and function by subject report and objective
measures of function. (J Pediatr 2015;167:731-7).
F
ibromyalgia is one of the most common amplified pain syndromes in children, occurring in 2%-6% of the pediatric pop-
ulation.1-5 It is defined as widespread pain lasting at least 3 months and, depending on criteria, associated with between 5
and 11 of 18 trigger points, along with other somatic complaints, such as irritable bowel syndrome, fatigue, unrestorative
sleep, and chronic headache.6,7 Girls predominate at a rate of approximately 4:1, and the disorder seems to affect Caucasians
disproportionately.8 The etiology is unknown, but some of the factors associated with adults with fibromyalgia include depres-
sion,5,9 low pain threshold,2 cortisol dysregulation,10,11 and ischemia.12-14 Adult fibromyalgia criteria are applied in diagnosing
these children, and as such other potential etiologies need to be ruled out before a diagnosis can be made. No criteria have been
established for the diagnosis of fibromyalgia in children.
Treatment of childhood fibromyalgia has remained elusive, with the major focus on cognitive behavioral therapy15-17 and
aerobic training.18,19 Studies of long-term outcomes have reported persistent pain in more than 90% of affected children,
and sleep disturbance was found in more than 90% of 33 children with fibromyalgia surveyed 2.6 years after diagnosis.20,21
In a large cohort of children with fibromyalgia, more than 80% had persistent symptoms into adulthood, and, compared
with controls, had more pain, anxiety, and medical visits, along with decreased physical function at 5.9 years after diagnosis.22
In adults, evidence-based guidelines stress cognitive behavioral therapy and aerobic training.23 Medications have little role in
treating children, and systematic reviews in adults are not encouraging.24-27
We have had short- and long-term success in treating children with complex regional pain syndrome with a very intensive
physical and occupational therapy (PT/OT) program along with psychological counseling,28 which has been replicated by
others.29,30 Although complex regional pain syndrome is a different pain diag-
nosis, children with this form of amplified pain are also treated in our program,From the 1Division of Rheumatology, and Departments of
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short-term functional outcomes in a small group of children
with fibromyalgia who underwent sleep studies before and af-
ter participating in the intensive PT/OT program with excel-
lent results.18
The objective of the present study was to compare a cohort
of patients with fibromyalgia on various objective and subjec-
tive measures at 3 time points: at admission to our program,
discharge from the program, and 1 year after completion of
the program.Methods
The study protocol was reviewed and approved by our hospi-
tal’s Committee for the Protection of Human Subjects. All
parents provided consent, and subjects provided assent
before study participation. The source population for the
study was children and adolescents aged 13-18 years with a
diagnosis of primary juvenile fibromyalgia treated in the
inpatient or day hospital amplifiedmusculoskeletal pain pro-
gram between September 2008 and May 2011. The subjects
were a convenience sample enrolled without regard to pain
duration, pain severity, or previous therapy. Children for
whom this was not the initial participation in the amplified
musculoskeletal pain program, as well as those whom
required modification of the program because of another
medical condition, such as cerebral palsy or fragile bones,
were excluded. One patient who consented to participate
was discharged from the program before completing any
therapy owing to high-level contact precautions (methi-
cillin-resistant Staphylococcus aureus carrier). All subjects ful-
filled the American College of Rheumatology’s 2010
fibromyalgia criteria.31
Intervention
Before participating in our program, the children were
encouraged to do aerobics and, if they had allodynia, to
desensitize. We frequently prescribed a formal home exercise
program and local physical therapy, although adherence was
not formally measured. All pain medications and medica-
tions given for fibromyalgia, such as analgesics, antiepilep-
tics, antidepressants, and sleep medications, were
discontinued. If the home exercise program was not success-
ful, then the dose of PT/OT was increased. It is these children
who are included in this report.
The children were treated either as day hospital patients
or inpatients. All children received individualized 1-on-1
therapy for 5-6 hours a day, with the focus on quickly re-
establishing normal function, along with maximizing aero-
bic conditioning. Activities typically included timed
activities (eg, animal walks, stepping in/out of a tub,
running up and down stairs, stepping and squatting
activity), scooter boards, treadmill, elliptical, stairs, long-
distance community ambulation, strengthening and endur-
ance activities, and dance or other video game activities.
Treatment goals were set high and quickly advanced as732the child progressed through the requirements to a higher
level of function and exercise. Children with allodynia
received multiple courses of desensitization, including
rubbing, local and total body vibration, constant light
touch or compression, temperature and noise desensitiza-
tion, fanning, and exposure to multiple different textures.
Desensitization was often incorporated into exercises
when possible. Children who experienced pain with eating
were often required to eat a minimum of 7 meals and
snacks per day.
The duration of therapy for each child was individually
determined by the treatment team based on physical func-
tioning goals obtained, rate of improvement, and judgment
regarding the child’s ability to sustain and further improve
on these functional goals in the home environment without
formal physical therapy.
Psychosocial support included both 1-on-1 and group ses-
sions with a psychologist for both cognitive and behavioral
therapy-based intervention, as well as support for coping
during PT/OT sessions, as indicated. Art therapy and music
therapy were also included, for a minimum of 4 hours per
week of psychosocial support. In addition, parent group ses-
sions were held weekly, and family or parent sessions were
added when indicated.
Objective
The objective of this study was to evaluate long-term func-
tional and psychosocial outcomes of the patients completing
our intensive program.
Outcome Measures
Bruce Treadmill Protocol32: This test consists of walking on a
treadmill until the subject is unable to continue walking or
running owing to exhaustion or pain. The test increases in
speed and incline every 3 minutes until the subject cannot
continue or he or she completes the test time of 21 minutes.
The patient is allowed to hold the handrail(s) of the treadmill
if he or she chooses. The test results can be compared with
age- and sex-matched norms.
Bruininks-Oseretsky Test of Motor Performance, Second
Edition (BOT-2)33: This test measures gross and fine motor
function, as well as balance and coordination. It consists of
8 subtests: fine motor control, fine motor integration,
manual dexterity, bilateral coordination, balance, running
speed and agility, upper limb coordination, and strength.
The scores on these subtests are summed to calculate a total
composite score, which is then interpreted based on age- and
sex-matched norms. For each subtest, higher scores represent
better performance.
Functional Disability Inventory (FDI)34: This self-report
measure asks the subject to rate how much physical
“trouble” he or she experiences related to pain when at-
tempting to complete various functional activities. Re-
sponses include “no trouble,” “a little trouble,” “some
trouble,” “a lot of trouble,” and “impossible.” These rat-
ings are given a number equivalent. These numbers are
summed to arrive at a final score ranging from 0 to 60,Sherry et al
September 2015 ORIGINAL ARTICLESwith lower scores indicating higher levels of function and
higher scores indicating higher levels of disability due to
pain.
Pain Stages of Change Questionnaire, adolescent version
(PSOCQ-A)35: This tool is based on Prochaska and DiCle-
mente’s transtheoretical model of behavior change, which as-
sesses an individual’s motivation to change and to engage in
treatment. When adapted for use in patients with chronic
pain, 4 stages of change are identified: precontemplation
(no clear sense of responsibility for pain control or need to
make behavioral change), contemplation (some awareness
of responsibility for pain control and some need to make
behavioral change), action (actively taking responsibility
for pain control and making behavioral change), and main-
tenance (maintaining responsibility for pain control and
maintaining behavioral change). The subject responds to
each of the 30 items on this measure on a 5-point scale
ranging from “strongly disagree” to “strongly agree.” This
measure is scored by summing the scores of the different
item numbers composing each of the 4 stages, and then
dividing that total by the number of items in that domain.
The higher a subject scores in a specific domain, the more
emphasis he or she is placing on that stage of change with re-
gard to readiness to take responsibility for the pain and make
behavioral changes.
Visual analog scale (VAS): To use this tool, the subject is
asked: “Howmuch pain are you in now?” The subject is given
a card on which is printed a 100-mm line and asked to mark
his or her level of pain intensity on the scale, with 0 mm being
no pain and 100 mm being the worst pain imaginable. This
scale has proven validity.36
Pediatric Quality of Life Inventory (PedsQL), Teen
Report (Mapi Research Trust, Lyon France)37-40: This 23
item self-report measure assesses health-related quality of
life in patients aged 13-18 years with regard to core health
dimensions, including physical functioning, emotional
functioning, social functioning, and school functioning.
The subject responds to questions assessing how often he
or she has problems in these domains on a 5-point scale
ranging from “never” to “almost always.” Items are
reverse-scored and transformed to a scale of 0-100. Mean
scores are then calculated for each core health dimension,
with lower scores indicating poorer quality of life.
Summary scores are also created. The psychosocial health
summary score is the sum of the emotional, social, and
school functioning scales. The physical health summary
score equals the physical functioning scale score. The total
score is the sum of all the items answered over all of the
scales.
All measures were administered once at each of the 3 study
time points.
Statistical Analyses
Demographic information and baseline characteristics are
summarized by frequency and percentage for categorical var-
iables (eg, race, pain diagnosis) and by mean and 95% CI or
median and IQR, as appropriate, for continuous or countThe Treatment of Juvenile Fibromyalgia with an Intensive Physicavariables (eg, age, duration of pain, duration of the intensive
program).
The median function, pain, and quality of life measures re-
corded at the following time points were compared using a
matched signed-rank test: preprogram clinic visit and pro-
gram entry, program entry and completion, and program
completion and 1 year after program completion. For those
subjects missing discharge measures (<15% for all measures),
sensitivity analyses were performed, which assumed no
improvement in scores from program entry to program
completion.Results
Subjects were recruited between 2008 and 2011, with follow
up continuing through 2012.
Baseline Data
Sixty-four of the 81 children and adolescents with primary
fibromyalgia who participated to The Children’s Hospital
of Philadelphia’s intensive pain program were enrolled
(79%). The enrolled subjects and those who were not
enrolled did not differ significantly in terms of pain intensity
(as measured by the VAS) at program entry. Demographic
data, duration of pain, and self-reported comorbid
psychiatric diagnoses are presented in Table I. Twenty-
three subjects (36%) had a concomitant diagnosis of
anxiety (n = 6), depression (n = 8), or both (n = 9).
Thirty-seven subjects (58%) were on pain medication other
than acetaminophen or a nonsteroidal anti-inflammatory
drug at the time of enrollment. All pain medications,
including acetaminophen and nonsteroidal anti-
inflammatory drugs, were stopped at the time of admission
to the program. The mean duration of the inpatient or day
hospital program was 23  13 days.
Subjects had to wait a median of 143 days from
program assessment to program entry (Table I). During
this period, they were encouraged to be active and
participate in outpatient PT/OT and counseling. During
the interval between program assessment and program
entry, the FDI score improved from 26 to 24, a slightly
significant change (P = .03) (Table II), and the pain score
dropped from 71 to 66, a nonsignificant change (P = .86)
(Table III).Outcomes and Estimation
Function. Scores for tests of function at program entry,
program completion, and 1 year after program completion
are shown in Table II. In every test of function, the
subjects’ performance improved significantly from
program entry to program completion (P < .001 for all).
Bruce scores decreased slightly over 1 year after
program completion, but scores at the 1-year follow-up
remained significantly better than those at program entry
(P < .001), and remained at or above the 90th percentile
for age- and sex-matched norms, compared with belowl and Psychosocial Program 733
Table I. Patient characteristics (n = 64)
Characteristics Value
Age, y, median (IQR) 16 (15-17)
Caucasian race, n (%) 62 (95)
Female sex, n (%) 60 (94)
Duration of symptoms, mo, median (IQR) 21 (11-36)
Wait for program entry, d, median (IQR) 143 (97-233)
Duration of intensive program, d, mean  SD 23  13
Comorbid psychiatric conditions, n (%)
Anxiety 15 (23)
Depression 17 (27)
Comorbid medical conditions, n (%)
Juvenile arthritis 3 (5)
Diabetes 2 (3)
Migraine/chronic headache 13 (20)
Sickle cell disease 1 (2)
Thyroid dysfunction 1 (2)
Lyme disease 2 (3)
Ehlers-Danlos syndrome 1 (2)
Psoriasis 1 (2)
Chiari malformation 2 (3)
Chronic kidney disease 1 (2)
FDI at program entry, median (IQR) 24 (17-31)
Pain VAS score at program entry, median (IQR) 66 (44-82)
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 167, No. 3the 25th percentile at admission. All domains of the BOT-2
remained stable at 1 year after program completion, as did
FDI scores.
We performed sensitivity analyses for each measure that
assumed anyone with missing discharge data (<11% for all
program entry and completion measures) did not have any
improvement in scores since program entry. Overall, across
all tests of function, there was still significant improvement
from program entry to program completion (P < .001 for
all).
Pain, Quality of Life, and Adolescent Clinical Inven-
tory. Scores for pain, quality of life, and the adolescent
clinical inventory at program entry, program completion,
and 1 year after program completion are shown in
Table III. Subject-reported pain as measured on a VAS
improved significantly from program entry to program
completion and continued to improve (albeit not to a
statistically significant degree) to 1 year after program
completion. Of the 54 subjects who had a pain VAS




program entry Program entry
Program
completion
Bruce - 588 (429-661) 801 (739-908
BOT-2 -
Fine manual control 31 (16-54) 48 (31-73)
Manual coordination 31 (16-62) 73 (54-92)
Body coordination 21 (8-49) 46 (27-66)
Strength and agility 35 (14-58) 65 (35-79)
Total motor composite 24 (8-46) 54 (35-84)
FDI 26 (20-33) 24 (17-31) 7 (3-20)
734a score of 0/100, indicating no pain, and 26 (48%) had a
score of 10/100 or less.
The PSOCQ-A scores suggest that over the course of the
program, the subjects tended to shift toward taking more
active steps to address their pain, and that they tended to
remain active in addressing the pain and maintaining gains
(Table III). Specifically, the scores indicate a significant
decrease in precontemplation between program entry and
program completion, along with a nonsignificant decrease
between program completion and 1-year follow-up.
Contemplation increased significantly between program
entry and program completion and remained stable between
program completion and follow-up. The PSOCQ-A scores
also indicate a statistically significant increase in action
between program entry and program completion and also
between program completion and 1-year follow-up.
Similarly, maintenance scores also increased significantly
between program entry and program completion, but
showed no significant change between program completion
and 1-year follow-up.
Subject-reported quality of life as measured by the
PedsQL, Teen Report significantly improved from program
entry to program completion (Table III). The total,
physical health summary, psychosocial health summary,
and school functioning scores continued to improve
significantly throughout the year after program
completion. Emotional functioning and social functioning
remained stable throughout this period.
Discussion
Our children with long-standing fibromyalgia exhibited sig-
nificant improvement in nearly all of the functional and pain
measures that we applied. Function, as measured by the FDI,
went from the moderately disabled category to normal34 and
remained normal for the year after program completion. The
BOT-2 battery continued to improve significantly over that
1-year period. The Bruce protocol times improved signifi-
cantly and remained quite high at the 1-year follow-up,
demonstrating durability of aerobic endurance. Although
there was a dropoff in the mean time at the 1-year follow-
up, it remained at the 90th percentile for normal children.32
It is understandable that at the end of the intensive PT/OTP value
1-year follow-up Program entry vs end
Program completion
vs 1-year follow-up
) 750 (676-840) <.001 .005
60 (42-89) <.001 .07
86 (54-96) <.001 .09
46 (27-66) <.001 .69
66 (50-76) <.001 .41
69 (38-86) <.001 .05
5 (2-18) <.001 .12
Sherry et al
Table III. Pain, adolescent clinical inventory, and quality of life
Tests






completion 1-y follow-up Entry vs end
End vs 1-y
follow-up
Pain VAS 71 (57-78) 66 (44-82) 25 (4-68) 20 (0-66) <.001 .05
PSOCQ-A -
Precontemplation 2.9 (2.4-3.4) 2.3 (2.0-2.9) 2.14 (1.6-2.9) <.001 .120
Contemplation 3.6 (3.1-3.9) 3.8 (3.3-4.2) 3.5 (3.0-3.9) .005 .018
Action 3.7 (3.2-4.0) 4.3 (4.0-4.8) 4.0 (3.3-4.3) <.001 .006
Maintenance 3.6 (3.0-4.0) 4.4 (4.0-4.9) 4.4 (4.0-5.0) <.001 .73
PedsQL, Teen Report -
Total score 48 (38-60) 66 (51-78) 78 (67-92) <.001 <.001
Physical health summary score 31 (22-47) 63 (44-81) 78 (59-94) <.001 <.001
Psychosocial health summary score 55 (45-67) 70 (55-78) 80 (67-92) <.001 .001
Emotional functioning 50 (40-65) 60 (55-85) 75 (55-85) <.001 .070
Social functioning 70 (50-80) 85 (70-95) 90 (75-100) <.001 .140
School functioning 50 (30-60) 55 (45-80) 80 (60-95) .002 <.001
September 2015 ORIGINAL ARTICLESprogram, these children would have well-above-average
endurance, and the fact that it remained at such a high level
at 1 year reinforces their reports of high-level function.
The subjective reported level of pain also decreased signif-
icantly, with a mean level of 20/100 at 1 year after program
completion. One-third of the subjects reported a pain level
of 0/100 and another 15% had a pain score between 1/100
and 10/100.
Program duration varied owing to the individualized na-
ture of the program for each subject. We set PT/OT goals
for each subject, and the duration of the program depended
on the achievement of those goals, which varied from child to
child. The wait time for our program was lengthy because of
the waiting list to enter the program, as well as the need to
obtain insurance approval; however, this provided an oppor-
tunity for us to assess the subjects as their own controls. To
fully assess for the observed improvement, we looked at
pain and FDI scores from the time of clinic assessment to
program entry (Tables II and III), and found no change in
pain during this interval. There was a very slight
improvement in function (2 points) on the FDI, but this
was not clinically meaningful. This demonstrates that the
changes observed throughout the program were real
observations and not representative of regression to the
mean or a natural course of the disorder.
All children were off pain medication during the intensive
PT/OT program, and none were on pain medication at the 1-
year follow-up. In our experience, medications in this popu-
lation lead to side effects and are ineffective, while also
perpetuating the sick role by suggesting that reliance on
medication is necessary for successful treatment. These chil-
dren are at great risk of overmedication and iatrogenic injury.
Our data are in marked contrast to those from a previous
study that used much less PT/OT.19 This parallels our expe-
rience in treating children with complex regional pain syn-
drome in whom PT/OT was ineffective, but with a much
less intensive program. Both the dose of PT/OT and the
quality of the therapy differed from traditional PT/OT, in
that we focused on desensitization and prolonged aerobics,The Treatment of Juvenile Fibromyalgia with an Intensive Physicastrengthening, and functional activities individualized to
the subjects, and did not inquire about pain or let pain or
the fear of pain stop them.We believe that this focus on func-
tion rather than pain helps children break the pain cycle and
overcome the long-standing functional and pain limitations
with which they presented.
An important aspect of our program is the emotional sup-
port of the child and family. Dealing with pain and the often-
long process of seeking diagnosis and appropriate treatment
is an arduous process, both physically and emotionally, for
children and their families. Psychotherapy focuses on using
cognitive behavioral therapy-based interventions to support
children through intensive PT/OT, as well as helping them
apply these strategies to coping with stress in life outside of
program demands that may be contributing to their pain.
Many children benefit from cotreatment during PT/OT to
help learn and use strategies in vivo. Group psychotherapy
sessions are also used, along with creative arts therapies to
help advance socioemotional goals. Psychotherapy recom-
mendations after the intensive program have included indi-
vidual, family, marital, and other therapy as indicated. The
psychological well being of our sample was significantly
improved at the end of 1 year, as demonstrated by the overall
improved quality of life and maintenance of a high level of
emotional and social functioning. Our finding of lower
school functioning at program completion than at the 1-
year follow-up is consistent with our program structure,
which recommends that patients do not engage in school-
work during intensive program treatment; however, school
functioning improves over the year postdischarge, likely as
children catch up on missed work, and remains at a higher
level owing to increased function and decreased pain, as
well as improvements in overall coping skills.
The philosophy of our program is that the children treat
their own pain while learning the tools for doing so in our
treatment program. It is our hope that because of this,
they will remain fully functional and free of pain in the
long term. No studies of this have been conducted to date,
however. That said, the psychological variables at play mayl and Psychosocial Program 735
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head on may reap greater rewards, especially for long-term
outcomes.5
A weakness of this study is that it was not a randomized or
controlled trial. Nonetheless, these children had long-
standing pain that did not remit with less-intensive therapy.
Others have reported cohorts of children with fibromyalgia
who exhibit minimal improvement up to 6 years postdiagno-
sis.20-22 The children in the present study were significantly
disabled and were able to achieve and maintain normal func-
tion by both self-report and objective measures over 1 year.
We speculate that most of these children will have the neces-
sarymental and physical capability to stay well, and if relapses
occur, will have the tools to self-reinstitute these measures
and resolve any new symptoms, as we have seen in children
with complex regional pain syndrome treated with such a
program.28,29
Children with fibromyalgia can be treated successfully
without the use of medications and can regain normal func-
tion, achieve remission or marked reduction of pain, and
experience increased quality of life with an interdisciplinary
approach that uses much more intensive PT/OT than is
common in most pain programs, along with cognitive,
behavioral, and other psychosocial supports. n
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